Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Hepatology International
Published in: Hepatology International 2/2022

01-04-2022 | Hepatitis B | Review Article

Management of hepatitis B virus reactivation due to treatment of COVID-19

Authors: Terry Cheuk-Fung Yip, Madeleine Gill, Grace Lai-Hung Wong, Ken Liu

Published in: Hepatology International | Issue 2/2022

Login to get access

Abstract

The world has made significant progress in developing novel treatments for COVID-19 since the pandemic began. Some treatments target the patient’s dysregulated inflammatory response during COVID-19 infection and may cause hepatitis B reactivation (HBVr) in patients with current or past hepatitis B virus (HBV) infection. This review summarizes the risk and management of HBVr due to different treatments of COVID-19 in patients who have current or past HBV infection. Abnormal liver function tests are common during COVID-19 infection. Current evidence suggests that current or past HBV infection is not associated with an increased risk of liver injury and severe disease in COVID-19 patients. Among patients who received high-dose corticosteroids, various immunosuppressive monoclonal antibodies and inhibitors of Janus kinase, the risk of HBVr exists, especially among those without antiviral prophylaxis. Data, however, remain scarce regarding the specific use of immunosuppressive therapies in COVID-19 patients with HBV infection. Some results are mainly extrapolated from patients receiving the same agents in other diseases. HBVr is a potentially life-threatening event following profound immunosuppression by COVID-19 therapies. Future studies should explore the use of immunosuppressive therapies in COVID-19 patients with HBV infection and the impact of antiviral prophylaxis on the risk of HBVr.
Literature
1.
2.
Global Hepatitis Report 2017. Geneva: World Health Organisation; 2017. Licence: CCBY-NC-SA 3.0 IGO.
3.
He Q, Zhang G, Gu Y, Wang J, Tang Q, Jiang Z, et al. Clinical characteristics of COVID-19 patients with pre-existing hepatitis B virus infection: a multicenter report. Am J Gastroenterol. 2021;116(2):420–421CrossRefPubMed
4.
Yip TC, Wong VW, Lui GC, Chow VC, Tse YK, Hui VW, et al. Current and past infections of HBV do not increase mortality in patients with COVID-19. Hepatology. 2021;74(4):1750–1765CrossRefPubMed
5.
Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382(18):1708–1720CrossRefPubMed
6.
Chen J, Qi T, Liu L, Ling Y, Qian Z, Li T, et al. Clinical progression of patients with COVID-19 in Shanghai. China J Infect. 2020;80(5):e1–e6CrossRefPubMed
7.
Li Y, Li C, Wang J, Zhu C, Zhu L, Ji F, et al. A case series of COVID-19 patients with chronic hepatitis B virus infection. J Med Virol. 2020;92(11):2785–2791CrossRefPubMed
8.
Zou X, Fang M, Li S, Wu L, Gao B, Gao H, et al. Characteristics of liver function in patients with SARS-CoV-2 and chronic HBV coinfection. Clin Gastroenterol Hepatol. 2021;19(3):597–603CrossRefPubMed
9.
Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW, et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area. JAMA. 2020;323(20):2052–2059CrossRefPubMedPubMedCentral
10.
11.
Loomba R, Liang TJ. Hepatitis B reactivation associated with immune suppressive and biological modifier therapies: current concepts, management strategies, and future directions. Gastroenterology. 2017;152(6):1297–1309CrossRefPubMed
12.
Lau G, Yu ML, Wong G, Thompson A, Ghazinian H, Hou JL, et al. APASL clinical practice guideline on hepatitis B reactivation related to the use of immunosuppressive therapy. Hep Intl. 2021;15(5):1031–1048CrossRef
13.
Scobie HM, Johnson AG, Suthar AB, Severson R, Alden NB, Balter S, et al. Monitoring Incidence of COVID-19 Cases, Hospitalizations, and Deaths, by Vaccination Status - 13 U.S. Jurisdictions, April 4–July 17, 2021. MMWR Morb Mortal Wkly Rep. 2021;70(37):1284–90.
14.
Garg S, Kim L, Whitaker M, Acosta AM, Pham H, Whitaker M, et al. Hospitalization rates and characteristics of patients hospitalized with laboratory-confirmed coronavirus disease 2019—COVID-NET, 14 states, March 1–30, 2020. MMWR Morb Mortal Wkly Rep. 2021;69(15):458–464CrossRef
15.
Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2021;397(10285):1637–45.
16.
Benfield T, Bodilsen J, Brieghel C, Harboe ZB, Helleberg M, Holm C, et al. Improved survival among hospitalized patients with COVID-19 treated with remdesivir and dexamethasone. A nationwide population-based cohort study. Clin Infect Dis. 2021.
17.
Kalil AC, Patterson TF, Mehta AK, Tomashek KM, Wolfe CR, Ghazaryan V, et al. Baricitinib plus remdesivir for hospitalized adults with COVID-19. N Engl J Med. 2021;384(9):795–807CrossRefPubMed
18.
Veiga VC, Prats J, Farias DLC, Rosa RG, Dourado LK, Zampieri FG, et al. Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial. BMJ. 2021;372:n84.
19.
REMAP-CAP Investigators GA, Mouncey PR, et al. Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19. New England Journal of Medicine. 2021;384(16):1491–502.
20.
Guimarães PO, Quirk D, Furtado RH, Maia LN, Saraiva JF, Antunes MO, et al. Tofacitinib in patients hospitalized with COVID-19 pneumonia. N Engl J Med. 2021;385(5):406–415CrossRefPubMed
21.
Stebbing J, Phelan A, Griffin I, Tucker C, Oechsle O, Smith D, et al. COVID-19: combining antiviral and anti-inflammatory treatments. Lancet Infect Dis. 2020;20(4):400–402CrossRefPubMedPubMedCentral
22.
Wong GL, Wong VW, Thompson A, Jia J, Hou J, Lesmana CRA, et al. Management of patients with liver derangement during the COVID-19 pandemic: an Asia-Pacific position statement. Lancet Gastroenterol Hepatol. 2020;5(8):776–787CrossRefPubMedPubMedCentral
23.
Bertolini A, van de Peppel IP, Bodewes F, Moshage H, Fantin A, Farinati F, et al. Abnormal liver function tests in patients with COVID-19: relevance and potential pathogenesis. Hepatology. 2020;72(5):1864–1872CrossRefPubMed
24.
Yip TC, Lui GC, Wong VW, Chow VC, Ho TH, Li TC, et al. Liver injury is independently associated with adverse clinical outcomes in patients with COVID-19. Gut. 2021;70(4):733–742CrossRefPubMed
25.
26.
Marjot T, Webb GJ, Barritt ASt, Moon AM, Stamataki Z, Wong VW, et al. COVID-19 and liver disease: mechanistic and clinical perspectives. Nat Rev Gastroenterol Hepatol. 2021;18(5):348–64.
27.
Lv Y, Zhao X, Wang Y, Zhu J, Ma C, Feng X, et al. Abnormal Liver Function Tests Were Associated With Adverse Clinical Outcomes: An Observational Cohort Study of 2,912 Patients With COVID-19. Front Med (Lausanne). 2021;8:639855.
28.
Balderramo D, Mattos AZ, Mulqui V, Chiesa T, Placido-Damian Z, Abarca J, et al. Abnormal liver tests during hospitalization predict mortality in patients with COVID-19: a multicenter study from South America. Can J Gastroenterol Hepatol. 2021;2021:1622533CrossRefPubMedPubMedCentral
29.
Middleton P, Hsu C, Lythgoe MP. Clinical outcomes in COVID-19 and cirrhosis: a systematic review and meta-analysis of observational studies. BMJ Open Gastroenterol. 2021;8(1).
30.
Hippisley-Cox J, Coupland CA, Mehta N, Keogh RH, Diaz-Ordaz K, Khunti K, et al. Risk prediction of covid-19 related death and hospital admission in adults after covid-19 vaccination: national prospective cohort study. BMJ. 2021;374:n2244.
31.
Ding ZY, Li GX, Chen L, Shu C, Song J, Wang W, et al. Association of liver abnormalities with in-hospital mortality in patients with COVID-19. J Hepatol. 2021;74(6):1295–1302CrossRefPubMed
32.
Chen L, Huang S, Yang J, Cheng X, Shang Z, Lu H, et al. Clinical characteristics in patients with SARS-CoV-2/HBV co-infection. J Viral Hepat. 2020;27(12):1504–1507CrossRefPubMed
33.
Liu R, Zhao L, Cheng X, Han H, Li C, Li D, et al. Clinical characteristics of COVID-19 patients with hepatitis B virus infection - a retrospective study. Liver Int. 2021;41(4):720–730CrossRefPubMed
34.
Kang SH, Cho DH, Choi J, Baik SK, Gwon JG, Kim MY. Association between chronic hepatitis B infection and COVID-19 outcomes: A Korean nationwide cohort study. PLoS One. 2021;16(10):e0258229.
35.
Sodeifian F, Seyedalhosseini ZS, Kian N, Eftekhari M, Najari S, Mirsaeidi M, et al. Drug-Induced Liver Injury in COVID-19 Patients: A Systematic Review. Front Med (Lausanne). 2021;8:731436.
36.
Wong GL, Yip TC, Wong VW, Tse YK, Hui DS, Lee SS, et al. SARS-CoV-2 Viral Persistence Based on Cycle Threshold Value and Liver Injury in Patients With COVID-19. Open Forum Infect Dis. 2021;8(6):ofab205.
37.
Zacharioudakis IM, Prasad PJ, Zervou FN, Basu A, Inglima K, Weisenberg SA, et al. Association of SARS-CoV-2 genomic load with outcomes in patients with COVID-19. Ann Am Thorac Soc. 2021;18(5):900–903CrossRefPubMedPubMedCentral
38.
39.
Reddy KR, Beavers KL, Hammond SP, Lim JK, Falck-Ytter YT, American Gastroenterological Association I. American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. Gastroenterology. 2015;148(1):215–9; quiz e16–7.
40.
Rodriguez-Tajes S, Miralpeix A, Costa J, Lopez-Sune E, Laguno M, Pocurull A, et al. Low risk of hepatitis B reactivation in patients with severe COVID-19 who receive immunosuppressive therapy. J Viral Hepat. 2021;28(1):89–94CrossRefPubMed
41.
Karam S, Wali RK. Current state of immunosuppression: past, present, and future. Crit Rev Eukaryot Gene Expr. 2015;25(2):113–134CrossRefPubMed
42.
Braun-Moscovici Y, Braun M, Saadi T, Markovits D, Nahir MA, Balbir-Gurman A. Safety of corticosteroid treatment in rheumatologic patients with markers of hepatitis B viral infection: pilot evaluation study. J Clin Rheumatol. 2016;22(7):364–368CrossRefPubMed
43.
Wong GL, Yuen BW, Chan HL, Tse YK, Yip TC, Lam KL, et al. Impact of dose and duration of corticosteroid on the risk of hepatitis flare in patients with chronic hepatitis B. Liver Int. 2019;39(2):271–279CrossRefPubMed
44.
Wong GL, Wong VW, Yuen BW, Tse YK, Yip TC, Luk HW, et al. Risk of hepatitis B surface antigen seroreversion after corticosteroid treatment in patients with previous hepatitis B virus exposure. J Hepatol. 2020;72(1):57–66CrossRefPubMed
45.
Hösel M, Quasdorff M, Wiegmann K, Webb D, Zedler U, Broxtermann M, et al. Not interferon, but interleukin-6 controls early gene expression in hepatitis B virus infection. Hepatology. 2009;50(6):1773–1782CrossRefPubMed
46.
Biehl A, Harinstein L, Brinker A, Glaser R, Munoz M, Avigan M. A case series analysis of serious exacerbations of viral hepatitis and non-viral hepatic injuries in tocilizumab-treated patients. Liver Int. 2021;41(3):515–528CrossRefPubMed
47.
Sonneveld MJ, Murad SD, van der Eijk AA, de Man RA. Fulminant liver failure due to hepatitis B reactivation during treatment with tocilizumab. ACG Case Rep J. 2019;6(12):e00243.
48.
Chen LF, Mo YQ, Jing J, Ma JD, Zheng DH, Dai L. Short-course tocilizumab increases risk of hepatitis B virus reactivation in patients with rheumatoid arthritis: a prospective clinical observation. Int J Rheum Dis. 2017;20(7):859–869CrossRefPubMed
49.
Kuo MH, Tseng CW, Lu MC, Tung CH, Tseng KC, Huang KY, et al. Risk of Hepatitis B Virus Reactivation in Rheumatoid Arthritis Patients Undergoing Tocilizumab-Containing Treatment. Dig Dis Sci. 2021.
50.
Chen M-H, Chen M-H, Liu C-Y, Tsai C-Y, Huang D-F, Lin H-Y, et al. Hepatitis B virus reactivation in rheumatoid arthritis patients undergoing biologics treatment. J Infect Dis. 2016;215(4):566–573
51.
Campbell C, Andersson MI, Ansari MA, Moswela O, Misbah SA, Klenerman P, et al. Risk of Reactivation of Hepatitis B Virus (HBV) and Tuberculosis (TB) and Complications of Hepatitis C Virus (HCV) Following Tocilizumab Therapy: A Systematic Review to Inform Risk Assessment in the COVID-19 Era. Front Med (Lausanne). 2021;8:706482.
52.
Fukuda W, Hanyu T, Katayama M, Mizuki S, Okada A, Miyata M, et al. Risk stratification and clinical course of hepatitis B virus reactivation in rheumatoid arthritis patients with resolved infection: final report of a multicenter prospective observational study at Japanese Red Cross Hospital. Arthritis Res Ther. 2019;21(1):255CrossRefPubMedPubMedCentral
53.
Watanabe R, Hashimoto M, Morinobu A. Correspondence on 'The use of tocilizumab and tofacitinib in patients with resolved hepatitis B infection: a case series'. Ann Rheum Dis. 2020.
54.
Schwaneck EC, Krone M, Kreissl-Kemmer S, Weissbrich B, Weiss J, Tony HP, et al. Management of anti-HBc-positive patients with rheumatic diseases treated with disease-modifying antirheumatic drugs-a single-center analysis of 2054 patients. Clin Rheumatol. 2018;37(11):2963–2970CrossRefPubMed
55.
Xu C, Rafique A, Potocky T, Paccaly A, Nolain P, Lu Q, et al. Differential binding of sarilumab and tocilizumab to IL-6Rα and effects of receptor occupancy on clinical parameters. J Clin Pharmacol. 2021;61(5):714–724CrossRefPubMed
56.
Gritti G, Raimondi F, Bottazzi B, Ripamonti D, Riva I, Landi F, et al. Siltuximab downregulates interleukin-8 and pentraxin 3 to improve ventilatory status and survival in severe COVID-19. Leukemia. 2021;35(9):2710–2714CrossRefPubMedPubMedCentral
57.
Boor PPC, de Ruiter PE, Asmawidjaja PS, Lubberts E, van der Laan LJW, Kwekkeboom J. JAK-inhibitor tofacitinib suppresses interferon alfa production by plasmacytoid dendritic cells and inhibits arthrogenic and antiviral effects of interferon alfa. Transl Res. 2017;188:67–79CrossRefPubMed
58.
Dong Y, Li X, Yu Y, Lv F, Chen Y. JAK/STAT signaling is involved in IL-35-induced inhibition of hepatitis B virus antigen-specific cytotoxic T cell exhaustion in chronic hepatitis B. Life Sciences. 2020;252:117663.
59.
Chen YM, Huang WN, Wu YD, Lin CT, Chen YH, Chen DY, et al. Reactivation of hepatitis B virus infection in patients with rheumatoid arthritis receiving tofacitinib: a real-world study. Ann Rheum Dis. 2018;77(5):780–782CrossRefPubMed
60.
Serling-Boyd N, Mohareb AM, Kim AY, Hyle EP, Wallace ZS. The use of tocilizumab and tofacitinib in patients with resolved hepatitis B infection: a case series. Ann Rheum Dis. 2021;80(2):274–276CrossRefPubMed
61.
Wang ST, Tseng CW, Hsu CW, Tung CH, Huang KY, Lu MC, et al. Reactivation of hepatitis B virus infection in patients with rheumatoid arthritis receiving tofacitinib. Int J Rheum Dis. 2021.
62.
Harigai M, Winthrop K, Takeuchi T, Hsieh TY, Chen YM, Smolen JS, et al. Evaluation of hepatitis B virus in clinical trials of baricitinib in rheumatoid arthritis. RMD Open. 2020;6(1).
63.
Mohareb AM, Patel NJ, Fu X, Kim AY, Wallace ZS, Hyle EP. Screening for hepatitis B virus prior to initiating tocilizumab and tofacitinib in patients with rheumatologic diseases: a cross-sectional study. J Rheumatol. 2021.
64.
Terrault NA, Lok ASF, McMahon BJ, Chang KM, Hwang JP, Jonas MM, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018;67(4):1560–1599CrossRefPubMed
65.
Sarin SK, Kumar M, Lau GK, Abbas Z, Chan HL, Chen CJ, et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hep Intl. 2016;10(1):1–98CrossRef
66.
Wong GL, Chan HL, Yuen BW, Tse YK, Luk HW, Yip TC, et al. The safety of stopping nucleos(t)ide analogue treatment in patients with HBeAg-negative chronic hepatitis B. Liver Int. 2020;40(3):549–557CrossRefPubMed
67.
Yip TC, Wong GL, Wong VW, Tse YK, Lui GC, Lam KL, et al. Durability of hepatitis B surface antigen seroclearance in untreated and nucleos(t)ide analogue-treated patients. J Hepatol. 2017.
68.
European Association for the Study of the Liver. Electronic address eee, European Association for the Study of the L. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67(2):370–98.
69.
Wong GL, Seto WK, Wong VW, Yuen MF, Chan HL. Review article: long-term safety of oral anti-viral treatment for chronic hepatitis B. Aliment Pharmacol Ther. 2018;47(6):730–737CrossRefPubMed
70.
Yip TC, Wong GL. Current knowledge of occult hepatitis B infection and clinical implications. Semin Liver Dis. 2019;39(2):249–260CrossRefPubMed
71.
Nakamura J, Nagashima T, Nagatani K, Yoshio T, Iwamoto M, Minota S. Reactivation of hepatitis B virus in rheumatoid arthritis patients treated with biological disease-modifying antirheumatic drugs. Int J Rheum Dis. 2016;19(5):470–475CrossRefPubMed
72.
Lin CT, Huang WN, Hsieh CW, Chen YM, Chen DY, Hsieh TY, et al. Safety and effectiveness of tocilizumab in treating patients with rheumatoid arthritis - a three-year study in Taiwan. J Microbiol Immunol Infect. 2019;52(1):141–150CrossRefPubMed
73.
Watanabe T, Fukae J, Fukaya S, Sawamukai N, Isobe M, Matsuhashi M, et al. Incidence and risk factors for reactivation from resolved hepatitis B virus in rheumatoid arthritis patients treated with biological disease-modifying antirheumatic drugs. Int J Rheum Dis. 2019;22(4):574–582CrossRefPubMed
74.
Ahn SS, Jung SM, Song JJ, Park YB, Park JY, Lee SW. Safety of tocilizumab in rheumatoid arthritis patients with resolved hepatitis B virus infection: data from real-world experience. Yonsei Med J. 2018;59(3):452–456CrossRefPubMedPubMedCentral
75.
Mok CC, Chan KY, Lee KL, Tam LS, Lee KW. Factors associated with withdrawal of the anti-TNFα biologics in the treatment of rheumatic diseases: data from the Hong Kong Biologics Registry. Int J Rheum Dis. 2014;17(Suppl 3):1–8PubMed
Metadata
Title
Management of hepatitis B virus reactivation due to treatment of COVID-19
Authors
Terry Cheuk-Fung Yip
Madeleine Gill
Grace Lai-Hung Wong
Ken Liu
Publication date
01-04-2022
Publisher
Springer India
Published in
Hepatology International / Issue 2/2022
Print ISSN: 1936-0533
Electronic ISSN: 1936-0541
DOI
https://doi.org/10.1007/s12072-022-10306-x

Other articles of this Issue 2/2022

Hepatology International 2/2022 Go to the issue

Original Article

Image-matching digital macro-slide—a novel pathological examination method for microvascular invasion detection in hepatocellular carcinoma

Original Article

Abnormal bile acid-microbiota crosstalk promotes the development of hepatocellular carcinoma

Letter to the Editor

Are immune-checkpoint inhibitors immunosuppressive to hepatitis B virus?

Original Article

Serum TERT C228T is an important predictor of non-viral liver cancer with fatty liver disease

Letter to the Editor

‘Hepatic tuberculosis: a sheep in wolf’s clothing’. Author response

Correction

Correction to: The association between metabolic risk factors, nonalcoholic fatty liver disease, and the incidence of liver cancer: a nationwide population-based cohort study
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits